Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Equity Ratio (2020 - 2025)

Rani Therapeutics Holdings has reported Equity Ratio over the past 6 years, most recently at 0.71 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.71 for Q4 2025, up 642.69% from a year ago — trailing twelve months through Dec 2025 was 0.71 (up 642.69% YoY), and the annual figure for FY2025 was 0.71, up 642.69%.
  • Equity Ratio for Q4 2025 was 0.71 at Rani Therapeutics Holdings, up from 0.78 in the prior quarter.
  • Over the last five years, Equity Ratio for RANI hit a ceiling of 0.98 in Q4 2021 and a floor of 1.6 in Q2 2021.
  • Median Equity Ratio over the past 5 years was 0.49 (2023), compared with a mean of 0.3.
  • Peak annual rise in Equity Ratio hit 642.69% in 2025, while the deepest fall reached 684.47% in 2025.
  • Rani Therapeutics Holdings' Equity Ratio stood at 0.98 in 2021, then plummeted by 30.01% to 0.69 in 2022, then tumbled by 35.87% to 0.44 in 2023, then tumbled by 78.3% to 0.1 in 2024, then soared by 642.69% to 0.71 in 2025.
  • The last three reported values for Equity Ratio were 0.71 (Q4 2025), 0.78 (Q3 2025), and 0.54 (Q2 2025) per Business Quant data.